Sjogren's Syndrome
Chronic inflammatory and autoimmune disease in which the salivary and lacrimal glands undergo progressive destruction by lymphocytes and plasma cells resulting in decreased production of saliva and tears. The primary form, often called sicca syndrome, involves both KERATOCONJUNCTIVITIS SICCA and XEROSTOMIA. The secondary form includes, in addition, the presence of a connective tissue disease, usually rheumatoid arthritis.
Drugs by status
Approved for this indication (2)
Phase 4 trials (26)
- 23-valent pneumococcal polysaccharide vaccine
- calcium carbonate
- urea
- mirabegron
- castor oil
- dehydroepiandrosterone
- prednisone
- tacrolimus
- hydroxychloroquine
- autologous serum
- malic acid
- oxybutynin
- pneumococcal 13-valent conjugate vaccine
- belimumab
- cyclosporine
- tolterodine
- inactivated influenza vaccine
- varenicline
- rituximab
- solifenacin
- promestriene
- rebamipide
- citric acid
- varicella zoster virus glycoprotein e antigen
- olive
- iguratimod
Phase 3 trials (18)
Phase 2 trials (58)
- thalidomide
- allogeneic natural killer cells
- anifrolumab
- baminercept
- Branebrutinib
- Leniolisib
- cfz533
- tofacitinib
- efalizumab
- etanercept
- aldesleukin
- baricitinib
- levocarnitine
- ngx267
- p-552
- lulizumab pegol
- surfactant
- ro5459072
- rslv-132
- sirolimus
- mycophenolate
- ss-1
- leflunomide
- thymosin beta-4
- tirabrutinib
- xylitol
- allogeneic adipose derived mesenchymal stem cell
- cd19 car-t cells
- bifidobacterium bifidum
- upadacitinib
- +28 more
Phase 1 trials (19)
Organizations
Organization Involved with Phase 4 Indications (15)
- Alcon
- Allergan
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Region Skane
- Pontificia Universidad Catolica de Chile
- University of Lisbon
- Peking University
- Uppsala University
- Wize Pharma Inc
- University of Sao Paulo
- University of Gothenburg
- Dentaid
- Farmacias Ahumada
- University of Helsinki
- Hospital Nacional Profesor Alejandro Posadas
Organization Involved with Phase 3 Indications (15)
- Bristol-Myers Squibb
- Sanofi
- Aldeyra Therapeutics, Inc.
- Kissei Pharmaceuticals
- Cairo University
- Seoul National University
- Stanford University
- Universidad Nacional de Colombia
- University of Groningen
- University of Western Brittany
- University of Strasbourg
- University of Paris
- Government of France
- Federal University of Sao Paulo
- Hospital Dr. Sótero del Río
Organization Involved with Phase 2 Indications (59)
- Incyte
- Human Genome Sciences
- Galapagos NV
- Amgen
- Servier
- Roche
- Gilead Sciences
- MedImmune
- Biogen
- Novartis
- GlaxoSmithKline
- Parion Sciences
- RemeGen
- Resolve Therapeutics
- TorreyPines Therapeutics
- Otsuka
- Oklahoma Medical Research Foundation
- National Institutes of Health (NIH)
- National Eye Institute (NEI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute of Dental and Craniofacial Research (NIDCR)
- University of Pennsylvania
- University of Pittsburgh
- Azienda Ospedaliera S. Maria della Misericordia
- Chang Gung University
- Chung Shan Medical University
- Duke University
- Hoosier Cancer Research Network
- Kaohsiung Medical University
- Kresge Eye Institute
- +29 more
Organization Involved with Phase 1 Indications (11)
Organization Involved with Other Experimental Indications (10)